TRT dosing personalization: what the science actually supports

What did @invitewellnessllc actually say?

The creator argues that 100mg of testosterone per week is often too low for larger men, that no single dose works for everyone, and that starting too high creates side effects while starting too low can leave men in what they call "a synthetic testosterone deficiency." They also say that a testosterone level rising from 300 to 430 ng/dL does not necessarily mean a patient is optimized. The video is, broadly, a pitch for personalized TRT protocols at their clinic.

The core argument is not unreasonable. The framing around body size, starting dose philosophy, and the importance of blood work follow-up tracks with how many endocrinologists and urologists actually practice. But some of the language here gets loose in ways that matter clinically.

Does the science back this up?

Mostly, yes. Testosterone pharmacokinetics vary significantly between individuals, and body composition does affect distribution. The claim that one standardized dose is inadequate is well-supported.

A landmark paper by Bhasin et al. (2001, New England Journal of Medicine) demonstrated dose-dependent effects of testosterone on body composition and strength, with considerable individual variation in response at identical doses. More recently, Snyder et al. (2016, New England Journal of Medicine) in the Testosterone Trials showed that men achieved widely different serum testosterone levels on identical dosing protocols, reinforcing the case for individualized titration.

The creator's instinct to start lower and adjust upward also has clinical support. The Endocrine Society's 2018 clinical practice guidelines recommend initiating therapy at doses that achieve mid-normal serum testosterone concentrations, then adjusting based on response and tolerability. Starting aggressively high risks erythrocytosis, elevated hematocrit, and estradiol-related side effects that then require additional management.

What did they get wrong (or right)?

The concept of "synthetic testosterone deficiency" is where things get slippery. They got the phenomenon right but named it incorrectly, and that naming matters.

What they are describing is inadequate replacement, not a deficiency caused by the synthetic testosterone itself. When exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis but the replacement dose is insufficient to restore physiologic levels, the patient ends up with low testosterone plus suppressed endogenous production. That is real. But calling it "synthetic testosterone deficiency" implies the treatment itself created a new condition, which is misleading framing that could unnecessarily alarm patients or complicate their understanding of what is happening hormonally.

The 6'3", 250-pound example is anecdotal and clinically oversimplified. Body size correlates with volume of distribution, but it is not the primary driver of testosterone pharmacokinetics. Sex hormone-binding globulin levels, injection frequency, metabolism rate, and baseline testicular function all interact in ways that body weight alone does not predict. Presenting size as a primary dosing variable without those caveats is an oversimplification.

What they got right: follow-up labs are non-negotiable, a rise in total testosterone does not equal optimization, and free testosterone matters. These are accurate, important points that many patients and some clinicians miss.

What should you actually know?

TRT dosing is genuinely not one-size-fits-all, and this video is correct that a patient moving from 300 to 430 ng/dL is not automatically "optimized." The Endocrine Society defines the normal male range as roughly 300 to 1000 ng/dL, but optimal for any individual depends on symptom resolution, free testosterone, hematocrit, estradiol balance, and subjective well-being.

Here is what the video does not tell you:

• Total testosterone alone is an incomplete picture. Free testosterone, calculated or measured directly, is often more clinically relevant, particularly in men with elevated SHBG.
• Injection frequency matters as much as dose. Twice-weekly or more frequent injections reduce peak-to-trough variability, which can reduce side effects independent of total weekly dose.
• Hematocrit monitoring is not optional. TRT increases red blood cell production, and unmonitored erythrocytosis raises cardiovascular risk. The American Urological Association recommends checking hematocrit before starting and at 3 and 6 months.
• "Optimization" is not a single number. Symptom tracking tools like the Aging Males' Symptoms scale, combined with labs, give a more complete picture than any one testosterone value.

If a clinic is promising optimization without defining what that means for you specifically, that is a red flag, not a feature.